OncoCyte Corp (OCX) Cut to Sell at Zacks Investment Research
OncoCyte Corp (NYSE:OCX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Thursday.
According to Zacks, “OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. “
Several other analysts have also recently commented on the company. Canaccord Genuity reiterated a “buy” rating on shares of OncoCyte Corp in a report on Wednesday, June 15th. Benchmark Co. increased their price target on OncoCyte Corp from $7.50 to $8.00 and gave the stock a “speculative buy” rating in a report on Tuesday, June 7th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/15/oncocyte-corp-ocx-cut-to-sell-at-zacks-investment-research.html
Shares of OncoCyte Corp (NYSE:OCX) traded down 0.9975% during trading on Thursday, reaching $3.9799. 14,497 shares of the company were exchanged. The firm’s 50 day moving average price is $3.99 and its 200 day moving average price is $4.44. The company’s market capitalization is $101.21 million. OncoCyte Corp has a one year low of $2.45 and a one year high of $10.24.
OncoCyte Corp (NYSE:OCX) last announced its earnings results on Thursday, August 11th. The company reported ($0.10) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. Equities research analysts forecast that OncoCyte Corp will post $0.04 earnings per share for the current fiscal year.
OncoCyte Corp Company Profile
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.
Get a free copy of the Zacks research report on OncoCyte Corp (OCX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OncoCyte Corp Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for OncoCyte Corp and related companies with MarketBeat.com’s FREE daily email newsletter.